Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease

This study has been completed.
Information provided by:
Boehringer Ingelheim Identifier:
First received: July 2, 2009
Last updated: November 15, 2010
Last verified: November 2010

The study is intended to characterize the lung function profile of BI1744 in COPD patients where patients will perform pulmonary function tests at regular intervals for 24 hours at the end of a 6 week treatment period. Each patient will receive all four treatments.

Condition Intervention Phase
Pulmonary Disease, Chronic Obstructive
Drug: BI 1744 (Olodaterol) Low Dose
Drug: BI 1744 (Olodaterol) Medium Dose
Drug: Placebo
Drug: Foradil
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease

Resource links provided by NLM:

Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • The primary objective will be to evaluate whether once daily treatment with 5 mcg or 10 mcg BI 1744 administered via the Respimat device is superior to once daily treatment with Placebo Respimat using FEV1 AUC values [ Time Frame: 6 Weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • ECG [ Time Frame: 6 weeks ] [ Designated as safety issue: Yes ]
  • The key secondary objective will be to compare once daily treatment with 5 mcg or 10 mcg BI 1744 administered via the Respimat device is superior to twice daily treatment with Foradil Aerolizer using FEV1 AUC values. [ Time Frame: 6 Weeks ] [ Designated as safety issue: No ]
  • Additional endpoints of FEV1, FVC, FEV1 AUC [ Time Frame: 6 Weeks ] [ Designated as safety issue: No ]
  • Adverse Events [ Time Frame: 6 Weeks ] [ Designated as safety issue: Yes ]
  • Vital Signs [ Time Frame: 6 Weeks ] [ Designated as safety issue: Yes ]
  • Clinical Chemistry [ Time Frame: 6 Weeks ] [ Designated as safety issue: Yes ]

Enrollment: 100
Study Start Date: June 2009
Primary Completion Date: May 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BI1744 (Olodaterol)
Medium Dose once Daily
Drug: BI 1744 (Olodaterol) Medium Dose
BI1744 Respimat medium dose once daily and placebo Foradil
Experimental: BI 1744 (Olodaterol)
Low Dose once Daily
Drug: BI 1744 (Olodaterol) Low Dose
BI1744 Respimat low dose once daily and placebo Foradil
Placebo Comparator: Placebo
Placebo once Daily
Drug: Placebo
Placebo Respimat once daily and placebo Foradil
Active Comparator: Foradil
12 mcg twice daily
Drug: Foradil
12 mcg twice daily and placebo Respimat


Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients willing to participate with confirmed diagnosis of COPD
  • 40 years of age or older
  • having a 10 pack year smoking history
  • able to perform serial pulmonary function tests
  • able to use both a DPI and Respimat device

Exclusion Criteria:

Significant other disease

  • clinically relevant abnormal hematology, chemistry, or urinalysis
  • history of asthma
  • diagnosis of thyrotoxicosis
  • paroxysmal tachycardia related to beta agonists
  • history of MI within 1 year, cardiac arrhythmia, hospitalization for heart failure within 1 year
  • active tuberculosis, cystic fibrosis, clinically evident bronchiectasis
  • significant alcohol or drug use
  • pulmonary resection
  • taking oral beta adrenergics
  • taking unstable oral steroids
  • daytime oxygen
  • enrolled in rehabilitation program
  • enrolled in another study or taking investigational products
  • pregnant or nursing women, women of child bearing potential not willing to use two methods of birth control
  • those who are not willing to comply with pulmonary medication washouts
  Contacts and Locations
Please refer to this study by its identifier: NCT00932646

United States, Alabama
1222.25.25009 Boehringer Ingelheim Investigational Site
Jasper, Alabama, United States
United States, Florida
1222.25.25002 Boehringer Ingelheim Investigational Site
Clearwater, Florida, United States
1222.25.25003 Boehringer Ingelheim Investigational Site
Deland, Florida, United States
1222.25.25007 Boehringer Ingelheim Investigational Site
Winter Park, Florida, United States
United States, Georgia
1222.25.25010 Boehringer Ingelheim Investigational Site
Austell, Georgia, United States
United States, New Mexico
1222.25.25008 Boehringer Ingelheim Investigational Site
Albuquerque, New Mexico, United States
United States, North Carolina
1222.25.25012 Boehringer Ingelheim Investigational Site
Charlotte, North Carolina, United States
1222.25.25004 Boehringer Ingelheim Investigational Site
Raleigh, North Carolina, United States
United States, Ohio
1222.25.25011 Boehringer Ingelheim Investigational Site
Columbus, Ohio, United States
United States, South Carolina
1222.25.25014 Boehringer Ingelheim Investigational Site
Seneca, South Carolina, United States
United States, Tennessee
1222.25.25006 Boehringer Ingelheim Investigational Site
Knoxville, Tennessee, United States
United States, Texas
1222.25.25005 Boehringer Ingelheim Investigational Site
Houston, Texas, United States
United States, Virginia
1222.25.25013 Boehringer Ingelheim Investigational Site
Richmond, Virginia, United States
Sponsors and Collaborators
Boehringer Ingelheim
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

No publications provided

Responsible Party: Boehringer Ingelheim, Study Chair, Boehringer Ingelheim Identifier: NCT00932646     History of Changes
Other Study ID Numbers: 1222.25
Study First Received: July 2, 2009
Last Updated: November 15, 2010
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Chronic Disease
Lung Diseases
Respiration Disorders
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Disease Attributes
Pathologic Processes
Respiratory Tract Diseases
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Anti-Asthmatic Agents
Respiratory System Agents
Therapeutic Uses processed this record on April 16, 2014